[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 148
Citations 0
From JAMA's Daily News Site
July 3, 2013

From JAMA’s Daily News Site

JAMA. 2013;310(1):21. doi:10.1001/jama.2013.7753

For women with early-stage breast cancer, examining the tumor’s clinical characteristics and treatment already given is more effective than genetic tests in predicting the likelihood of recurrence more than 5 years after diagnosis, according to a recent study.

The analysis evaluated how effectively 5 scoring methods predicted recurrence in nearly 10 000 postmenopausal women with early-stage breast cancer. All 5 methods performed similarly during the first 5 years of the study. However, during 5 to 10 years of follow-up, the clinical treatment score was most effective in predicting recurrence. Two genetic tests also added significantly to the clinical treatment score’s ability to predict recurrence risk.

First Page Preview View Large
First page PDF preview
First page PDF preview
×